NHD Global
Growth Hormone & IGF · Source-reviewed dossier
Source-Reviewed Research Dossier
Sermorelin is a man-made 29-amino-acid piece of growth-hormone-releasing hormone (GHRH). GHRH is a natural signal from the brain that tells the pituitary, a small gland near the brain, to release growth hormone in pulses. Sermorelin has been studied as a way to encourage the body's own growth-hormone release, and historical articles discussed it for adult growth-hormone insufficiency. A separate analytical study looked at detecting it in urine for anti-doping. Neither record provides broad anti-aging, body-composition, or performance benefits. The research-catalog material is for laboratory investigation only, and its identity and lot quality depend on product-specific documents, not published clinical data.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2006 article reviewed sermorelin as an approach to adult-onset GH insufficiency.
The narrative perspective is not a modern controlled efficacy trial.
Read the primary studyA review described mass-spectrometric detection of GHRH analogues used in doping contexts.
Detection science informs identity and misuse monitoring, not therapeutic benefit.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The narrative perspective is not a modern controlled efficacy trial.
View primary recordDetection science informs identity and misuse monitoring, not therapeutic benefit.
View primary recordThird-party publications selected for direct relevance.
Clinical perspective. 2006. PMID 18046908.
Analytical review. 2021. PMID 34665524.
Concise answers for researchers comparing identity, evidence and catalog variants.
Two areas. A historical article discussed it for adult growth-hormone insufficiency, but that is a narrative view, not a controlled trial. A later analytical study used it to help develop urine detection methods for anti-doping. Neither shows anti-aging, fat loss, muscle building, or performance effects. So those wider claims are not supported by this evidence.
A 2006 narrative article discussed sermorelin as a possible approach for adult growth-hormone insufficiency, but such an article is not a controlled trial and cannot prove effectiveness. A later analytical study showed how to detect sermorelin and similar synthetic GHRH analogues in urine, which helps anti-doping monitoring. These two records answer different questions; neither validates a specific catalog lot or turns a growth-hormone response into a general health benefit.
The evidence base contains older clinical context and analytical identity/stability research rather than current broad-outcome trials.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Sermorelin is GHRH(1–29)-amide. Human research shows acute pituitary growth-hormone responses, while historical treatment data are limited and do not support modern anti-aging or performance…
Updated October 1, 2026
Sermorelin is an amidated 29-residue peptide corresponding to the active N-terminal region of human GHRH. The C-terminal amide is identity-defining.
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: SMO5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
